THE ROLE OF INDIVIDUAL NEUROINFLAMMATION MOLECULES IN PATHOGENESIS ISCHEMIC STROKE. PART II

The problem of cerebrovascular diseases, in particular acute cerebrovascular accident, does not lose its relevance. Despite the primary and secondary prevention of cardiovascular diseases, the incidence of ischemic stroke among the population of the Russian Federation remains high. A well-established system of routing patients with acute vascular accidents and a multidisciplinary approach to treatment do not always guarantee a satisfactory result. The widespread prevalence of the disease, a high degree of disability and mortality, a decrease in the age of patients, economic losses associated with the rehabilitation of patients and their long-term disability dictate the need to find new and effective approaches to the diagnosis and treatment of this condition.

Currently conducted studies are aimed at studying the pathogenetic cascade of reactions that occur at the time of acute cerebral ischemia, in order to develop adjuvant therapy. Based on the results obtained, additional options are being developed in the treatment and further rehabilitation of patients. The presented literature review collects and analyzes current data on the problem of ischemic stroke. The role of individual molecules of the tumor necrosis factor family, which are directly involved in the development and course of cerebral infarction, but also affect the further prognosis of survival and recovery of patients, is considered.

1. Wang H., Zhang S., Xie L., Zhong Z., Yan F. Neuroinflammation and peripheral immunity: Focus on ischemic stroke. International Immunopharmacology. 2023. 120 (1). 110332.

2. Ghelani D.P., Kim H.A., Zhang S.R., Drummond G.R., Sobey C.G., et al. Ischemic stroke and infection: A brief update on mechanisms and potential therapies. Biochemical Pharmacology. 2021. 193. 114768.

3. van Loo G., Bertrand M.JM. Death by TNF: a road to inflammation. Nature Reviews Immunology. 2023. 23 (5). 289–303.

4. Yuan S., Carter P., Bruzelius M., Vithayathil M., Kar S., et al. Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study. EBioMedicine. 2020. 59. 102956.

5. Kim H.J., et al. Role of TNF-α in neuroinflammation and neurodegeneration after ischemic stroke. Journal of Neuroinflammation. 2022. 19 (1). 123.

6. Mok H. J., et al. Balanced signaling through TNFR1 and TNFR2 in the central nervous system: Implications for stroke. Cell Reports. 2022. 39 (5). 110870.

7. Loga-Andrijić N., Petrović N.T., Filipović-Danić S., Marjanović S., Mitrović V., et al. The Significance of Interleukin-6 and Tumor Necrosis Factor-Alpha Levels in Cognitive Impairment among First-Ever Acute Ischaemic Stroke Patients. Psychiatria Danubina. 2021. 33. 37–42.

8. Sag D., Ayyildiz Z.O., Gunalp S., Wingender G. The role of TRAIL/DRs in the modulation of immune cells and responses. Cancers (Basel). 2019. 11. 1–34.

9. Ehrlich S., Infante-Duarte C., Seeger B., Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine. 2003. 21. 24 (6). 244–253.

10. Grosse-Wilde A., Voloshanenko O., Bailey S.L., Longton G.M., Schaefer U., et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. Journal of Clinical Investigation. 2008. 118. 100–110.

11. Rossin A., Miloro G., Hueber A.O. TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity. Cancers (Basel). 2019. 11. 639.

12. Kuang N., Shu B., Yang F., Li S., Zhang M. TRAIL or TRAIL-R2 as a Predictive Biomarker for Mortality or Cardiovascular Events: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology. 2023. 81 (5). 348–354.

13. Zakharyan E.A., Fomochkina I.I. Relationship of apoptosis markers with the severity of atherosclerotic lesions of the coronary arteries and clinical and instrumental characteristics of patients with coronary heart disease. Russian Journal of Cardiology. 2023. 11. 74–81.

14. Mihalovic M., Mikulenka P., Línková H., Neuberg M., Štětkářová I., et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Patients after Acute Stroke: Relation to Stroke Severity, Myocardial Injury, and Impact on Prognosis. Journal of Clinical Medicine. 2022. 11 (9). 2552.

15. Ratajczak W., Atkinson S.D., Kelly C. The TWEAK/Fn14/CD163 axis-implications for metabolic disease. Reviews in Endocrine and Metabolic Disorders. 2022. 23 (3). 449–462.

16. Inta I., Frauenknecht K., Dörr H., et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. Journal of the Neurological Sciences. 2008. 275. 117–120.

17. Cheadle L., Rivera S.A., Phelps J.S., et al. Sensory Experience Engages Microglia to Shape Neural Connectivity through a Non-Phagocytic Mechanism. Neuron (journal). 2020. 108. 451–468.

18. Nagy D., Ennis K.A., Wei R., et al. Developmental synaptic regulator, TWEAK/Fn14 signaling, is a determinant of synaptic function in models of stroke and neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 2021. 118.

19. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D, Cheung T.C. et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity. 1998. 8. 21–30.

20. Ware C.F., Croft M., Neil G.A. Realigning the LIGHT signaling network to control dysregulated inflammation. Journal of Experimental Medicine. 2022. 219.

21. Angerfors A., Brännmark C., Lagging C., Tai K., Månsby Svedberg R., et al. Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome. Journal of Neuroinflammation. 2023. 20 (1). 224.

22. Abraira L., López-Maza S., Quintana M., Fonseca E., Toledo M., et al. Exploratory study of blood biomarkers in patients with post-stroke epilepsy. European stroke journal. 2024. 9 (3). 763–771.